已选(0)清除
条数/页: 排序方式:
|
| All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文 JOURNAL OF HEPATOLOGY, 2019, 卷号: 70 作者: Gong, Guozhong; Wei, Lai; Xu, Xiaoyuan; Guan, Yujuan; Zheng, Sujun 收藏  |  浏览/下载:56/0  |  提交时间:2019/12/05 |
| Widespread and Functional RNA Circularization in Localized Prostate Cancer 期刊论文 CELL, 2019, 卷号: 176, 期号: 4 作者: Chen, Sujun; Huang, Vincent; Xu, Xin; Livingstone, Julie; Soares, Fraser 收藏  |  浏览/下载:71/0  |  提交时间:2019/12/05 |
| Complex ATP7B mutation patterns in Wilson disease and a evaluation of a yeast model for functional analysis of the individual variant 会议论文 作者: Chen, Yongpeng; Li, Xiaojin; Zhang, Wei; Zhou, Donghu; Lv, Tingxia 收藏  |  浏览/下载:37/0  |  提交时间:2019/12/05 |
| All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文 作者: Wei, Lai; Xu, Xiaoyuan; Guan, Yujuan; Zheng, Sujun; Sheng, Ji-Fang 收藏  |  浏览/下载:45/0  |  提交时间:2019/12/05 |
| Complex ATP7B mutation patterns in Wilson disease and evaluation of a yeast model for functional analysis of variants 期刊论文 HUMAN MUTATION, 2019, 卷号: 40, 期号: 5 作者: 收藏  |  浏览/下载:35/0  |  提交时间:2019/12/05
|
| THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文 作者: 收藏  |  浏览/下载:34/0  |  提交时间:2019/12/05 |
| All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文 作者: 收藏  |  浏览/下载:36/0  |  提交时间:2019/12/05 |
| THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文 作者: 收藏  |  浏览/下载:32/0  |  提交时间:2019/12/05 |
| All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文 作者: 收藏  |  浏览/下载:29/0  |  提交时间:2019/12/05 |
| Widespread and Functional RNA Circularization in Localized Prostate Cancer 期刊论文 Cell, 2019, 卷号: 176, 期号: 4, 页码: 831-843.e22 作者: 收藏  |  浏览/下载:25/0  |  提交时间:2019/12/23
|